The anti-STEAP1/PSMA ADC, DXC008: Assessment of anti-tumor efficacy, pharmacokinetic, and toxicity properties.
e17161 Background: Six-transmembrane epithelial antigen of prostate-1 (STEAP1) is highly expressed in multiple tumor types, including prostate cancer, Ewing’s sarcoma, gastric cancer, and ovarian cancer, making it a compelling therapeutic target. DXC008 is a novel dual-target antibody-drug conjugate (ADC) designed to target both STEAP1 and prostate-specific membrane antigen (PSMA), and utilizes a topoisomerase I inhibitor payload that disrupts DNA synthesis and effectively inhibits tumor cell proliferation. This study evaluated the preclinical efficacy, pharmacokinetics, and safety of DXC008. Methods: The pharmacological properties of DXC008 were evaluated in STEAP1/PSMA-positive cell lines, cell-derived xenograft (CDX) models, and rhesus monkeys. Key assessments included antitumor efficacy, pharmacokinetics, and preclinical safety, with toxicity evaluated in a two-month repeated-dose study. Results: DXC008 exhibited high affinity for both STEAP1 and PSMA, with efficient internalization into tumor cells. In vitro and in vivo studies demonstrated dose-dependent antitumor activity, with DXC008 outperforming single-target ADCs. Pharmacokinetic analysis showed DXC008 to have favorable characteristics, including high stability, prolonged half-life, and high systemic exposure. In toxicity studies, DXC008 was well-tolerated, with the highest non-severely toxic dose (HNSTD) of 40 mg/kg in rhesus monkeys. A phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic characteristics and efficacy of DXC008 at 2.8 mg/kg-28 mg/kg every 2 weeks in patients with advanced solid tumors is on-going. Conclusions: DXC008 exhibits a promising preclinical profile, including potent dual-target antitumor activity, favorable pharmacokinetics, and a well-tolerated safety profile. These findings demonstrate the potential of DXC008 to become a best-in-class (BIC) STEAP1/PSMA-targeting ADC, and to offer a favorable benefit-risk ratio for clinical development.
Authors
- Qingliang Yang (ORCID: https://orcid.org/0000-0002-6905-8484)
- Lu Bai (ORCID: https://orcid.org/0000-0003-1242-5412)
- Huihui� Guo (ORCID: https://orcid.org/0009-0002-4772-7381)
- Yuanyuan Huang
- Zhiwei Li (ORCID: https://orcid.org/0000-0002-2870-7265)
- Yong‐Xiang Chen (ORCID: https://orcid.org/0000-0003-3518-0139)
- Jiaojiao Yu
- Wenjun Li (ORCID: https://orcid.org/0000-0001-5335-7386)
- Zhixiang Guo (ORCID: https://orcid.org/0009-0006-1987-2660)
- Xiaoyan Zhao
- Lingli Zhang (ORCID: https://orcid.org/0000-0003-3316-010X)
- Binbin Chen (ORCID: https://orcid.org/0000-0001-5962-3147)
- Xiangfei Kong (ORCID: https://orcid.org/0000-0002-1550-4071)
- Miaomiao Chen (ORCID: https://orcid.org/0000-0002-4866-8072)
- You Zhou (ORCID: https://orcid.org/0000-0001-9250-0982)
- Jun Zheng (ORCID: https://orcid.org/0000-0003-2131-6816)
- Robert Y. Zhao
- Meng Dai (ORCID: https://orcid.org/0000-0002-8562-8889)
- Yunxia Zheng
- Junxiang Jia
Institutions
- Hangzhou DAC Biotech (China) (CN)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-05-28
- DOI
- https://doi.org/10.1200/jco.2025.43.16_suppl.e17161
- Citations
- 3
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 3.14